Managing Antithrombotic Therapy in Patients With Both Atrial Fibrillation and Coronary Heart Disease

• Published in: Clinical therapeutics 2014-09, Vol.36 (9), p.1176-1181
• Main Authors: Thompson, Peter L., MD, Verheugt, Freek W.A., MD
• Format: Article
• Language: English
• Subjects: Anticoagulants; Anticoagulants - therapeutic use; aspirin; Aspirin - therapeutic use; atrial fibrillation; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Cardiovascular disease; Coronary Artery Disease - complications; Coronary Artery Disease - drug therapy; coronary heart disease; Decision making; Drug therapy; Drug Therapy, Combination; Fibrinolytic Agents - therapeutic use; Heart attacks; Hemorrhage - chemically induced; Humans; Internal Medicine; Medical Education; P2Y12 antiplatelet agents novel oral anticoagulants; Platelet Aggregation Inhibitors - therapeutic use; Purinergic P2Y Receptor Antagonists - therapeutic use; Stroke; Stroke - prevention & control; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use; Vitamin K - antagonists & inhibitors; warfarin; Warfarin - therapeutic use
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2014.08.010

Abstract Purpose Atrial fibrillation (AF) and coronary heart disease (CHD) commonly occur together. Previous consensus guidelines were published before the wide availability of novel oral anticoagulants (NOACs) and newer P2Y12 antiplatelet agents. We examine recent evidence to guide management in 3 categories of patients with AF and CHD: patients with stable CHD, nonstented patients with recent acute coronary syndrome, and patients with a coronary stent requiring dual-antiplatelet therapy. Methods We conducted a literature search by evaluation of PubMed and other data sources including international meeting reports. We critically reviewed recent clinical trial and relevant registry evidence to update European and US consensus documents. Findings Oral anticoagulation with warfarin or NOACs is required to prevent embolic stroke in AF, and antiplatelet therapy is insufficient for this purpose. Antiplatelet therapy using monotherapy with aspirin is the standard of care in stable CHD. Dual-antiplatelet therapy with aspirin and clopidogrel or a new P2Y12 inhibitor (dual-antiplatelet therapy) is needed to reduce coronary events after an acute coronary syndrome or after percutaneous coronary intervention. Combinations of these agents increase the risk of bleeding, and limited clinical trial evidence suggests that withdrawal of aspirin may reduce bleeding without increasing coronary events. Implications Available clinical trials and registries provide remarkably little evidence to guide difficult clinical decision making in patients with combined AF and CHD. In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis. It is unclear whether this evidence applies to combinations of NOACs and newer P2Y12 inhibitors. Clinical trials of combinations of the newer antithrombotic agents are urgently needed to guide clinical care.